| Year |
Citation |
Score |
| 2021 |
Okaniwa M, Shibata A, Ochida A, Akao Y, White KL, Shackleford DM, Duffy S, Lucantoni L, Dey S, Striepen J, Yeo T, Mok S, Aguiar ACC, Sturm A, Crespo B, et al. Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Cytoplasmic Prolyl-tRNA Synthetase Inhibitors. Acs Infectious Diseases. PMID 33929818 DOI: 10.1021/acsinfecdis.1c00020 |
0.439 |
|
| 2020 |
Tanaka Y, Kurasawa O, Yokota A, Klein MG, Saito B, Matsumoto S, Okaniwa M, Ambrus-Aikelin G, Uchiyama N, Morishita D, Kimura H, Imamura S. New Series of Potent Allosteric Inhibitors of Deoxyhypusine Synthase. Acs Medicinal Chemistry Letters. 11: 1645-1652. PMID 34345355 DOI: 10.1021/acsmedchemlett.0c00331 |
0.426 |
|
| 2020 |
Tanaka Y, Kurasawa O, Yokota A, Klein MG, Ono K, Saito B, Matsumoto S, Okaniwa M, Ambrus-Aikelin G, Morishita D, Kitazawa S, Uchiyama N, Ogawa K, Kimura H, Imamura S. Discovery of Novel Allosteric Inhibitors of Deoxyhypusine Synthase. Journal of Medicinal Chemistry. PMID 32142284 DOI: 10.1021/acs.jmedchem.9b01979 |
0.392 |
|
| 2017 |
Ono K, Banno H, Okaniwa M, Hirayama T, Iwamura N, Hikichi Y, Murai S, Hasegawa M, Hasegawa Y, Yonemori K, Hata A, Aoyama K, Cary DR. Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives. Bioorganic & Medicinal Chemistry. PMID 28302507 DOI: 10.1016/j.bmc.2017.02.038 |
0.437 |
|
| 2017 |
Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell. 31: 424-435. PMID 28292440 DOI: 10.1016/J.Ccell.2017.01.014 |
0.617 |
|
| 2016 |
Hirayama T, Okaniwa M, Banno H, Kakei H, Ohashi A, Ohori M, Nambu T, Iwai K, Kawamoto T, Yokota A, Miyamoto M, Ishikawa T. Design and synthesis of fused bicyclic inhibitors targeting the L5 loop site of centromere-associated protein E. Bioorganic & Medicinal Chemistry Letters. PMID 27476141 DOI: 10.1016/j.bmcl.2016.07.038 |
0.307 |
|
| 2016 |
Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 534: 272-6. PMID 27279227 DOI: 10.1038/Nature17963 |
0.612 |
|
| 2016 |
Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny C, McWhirter C, Banaji A, Won H, Wong W, Berger M, Stanchina Ed, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM. Abstract 2147: Overcoming mTOR resistance mutations with a new generation mTOR inhibitor Cancer Research. 76: 2147-2147. DOI: 10.1158/1538-7445.Am2016-2147 |
0.616 |
|
| 2015 |
Ohashi A, Ohori M, Iwai K, Nambu T, Miyamoto M, Kawamoto T, Okaniwa M. A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity. Plos One. 10: e0144675. PMID 26649895 DOI: 10.1371/journal.pone.0144675 |
0.377 |
|
| 2015 |
Hirayama T, Okaniwa M, Banno H, Kakei H, Ohashi A, Iwai K, Ohori M, Mori K, Gotou M, Kawamoto T, Yokota A, Ishikawa T. Synthetic Studies on Centromere-Associated Protein-E (CENP-E) Inhibitors: 2. Application of Electrostatic Potential Map (EPM) and Structure-Based Modeling to Imidazo[1,2-a]pyridine Derivatives as Anti-Tumor Agents. Journal of Medicinal Chemistry. PMID 26372373 DOI: 10.1021/acs.jmedchem.5b00836 |
0.326 |
|
| 2015 |
Ohashi A, Ohori M, Iwai K, Nakayama Y, Nambu T, Morishita D, Kawamoto T, Miyamoto M, Hirayama T, Okaniwa M, Banno H, Ishikawa T, Kandori H, Iwata K. Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nature Communications. 6: 7668. PMID 26144554 DOI: 10.1038/ncomms8668 |
0.302 |
|
| 2015 |
Fan Q, Wong R, Novotny C, Okaniwa M, Nicolaides T, Shokat K, Weiss W. ATPS-94THIRD GENERATION mTOR INHIBITORS IN GLIOBLASTOMA Neuro-Oncology. 17: v39.2-v39. DOI: 10.1093/Neuonc/Nov204.94 |
0.62 |
|
| 2013 |
Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Research. 73: 7043-55. PMID 24121489 DOI: 10.1158/0008-5472.CAN-13-1825 |
0.649 |
|
| 2013 |
Okaniwa M, Hirose M, Arita T, Yabuki M, Nakamura A, Takagi T, Kawamoto T, Uchiyama N, Sumita A, Tsutsumi S, Tottori T, Inui Y, Sang BC, Yano J, Aertgeerts K, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. Journal of Medicinal Chemistry. 56: 6478-94. PMID 23906342 DOI: 10.1021/Jm400778D |
0.562 |
|
| 2012 |
Okaniwa M, Hirose M, Imada T, Ohashi T, Hayashi Y, Miyazaki T, Arita T, Yabuki M, Kakoi K, Kato J, Takagi T, Kawamoto T, Yao S, Sumita A, Tsutsumi S, et al. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. Journal of Medicinal Chemistry. 55: 3452-78. PMID 22376051 DOI: 10.1021/Jm300126X |
0.348 |
|
| Show low-probability matches. |